{
  "id": "mhgap#risk_safety_ce1a856e",
  "content": "lamotrigine plus sodium valproate, lithium, y Due to the high risk of teratogenic effect with\nolanzapine, and quetiapine outperformed sodium valproate, the GDG believed it was important\nplacebo for recurrence/relapse rate of to provide clear directions on the use of sodium\ndepressive episodes. valproate in women and girls with bipolar disorder\n98\n3. Recommendations\nin remission who are of childbearing potential and kidney and thyroid function, complete blood\ntherefore made a strong recommendation despite count, ECG and pregnancy tests before beginning\nthe low certainty of evidence. treatment where possible.\nRemarks\nResearch gaps\ny Remission is considered when there is absence of\ny Most of the evidence is from HICs. Further research is\nor minimal symptoms for several weeks. Remission,\nneeded in LMICs.\ndefined as the absence of or minimal symptoms\ny Further research is needed to consider the side-\nfor several weeks, was not necessarily an inclusion\neffects related to exposure to sodium valproate\ncriteria in the trials included in the reviews.\nexclusively through breast-milk. It is, though, noted\ny Maintenance therapy was used in the\nthat the amount of sodium valproate in breast-\nrecommendation to define continuation of\nmilk is extremely low and that the baby will likely",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "risk_safety",
      "screening_cues",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Risk Safety lamotrigine plus sodium valproate, lithium, y Due to the high risk of teratogenic effect with\nolanzapine, and quetiapine outperformed sodium valproate, the GDG believed it was important\nplacebo for recurrence/relapse rate of to provide clear directions on the use of sodium\ndepressive episodes. valproate in women and girls with bipolar disorder\n98\n3. Recommendations\nin remission who are of childbearing potential and kidney and thyroid function, complete blood\ntherefore made a strong recommendation despite count, ECG and pregnancy tests before beginning\nthe low certainty of evidence. treatment where possible.\nRemarks\nResearch gaps\ny Remission is considered when there is absence of\ny Most of the evidence is from HICs. Further research is\nor minimal symptoms for several weeks. Remission,\nneeded in LMICs.\ndefined as the absence of or minimal symptoms\ny Further research is needed to consider the side-\nfor several weeks, was not necessarily an inclusion\neffects related to exposure to sodium valproate\ncriteria in the trials included in the reviews.\nexclusively through breast-milk. It is, though, noted\ny Maintenance therapy was used in the\nthat the amount of sodium valproate in breast-\nrecommendation to define continuation of\nmilk is extremely low and that the baby will likely Lamotrigine plus sodium valproate, lithium, y due to the high nguy cơ of teratogenic effect with\nolanzapine, and quetiapine outperformed sodium valproate, the gdg believed it was important\nplacebo for recurrence/relapse ..."
}